Rinsho Shinkeigaku (Clinical Neurology)

Case Report

Clinical analysis of opticospinal multiple sclerosis (OSMS) presentation detecting anti-myelin oligodendrocyte glycoprotein (MOG) antibody

Satoshi Kitagawa, M.D.1), Takashi Osada, M.D., Ph.D.1), Kimihiko Kaneko, M.D., Ph.D.2)3), Toshiyuki Takahashi, M.D., Ph.D.2)4), Norihiro Suzuki, M.D., Ph.D.1)5) and Jin Nakahara, M.D., Ph.D.1)

1)Department of Neurology, Keio University School of Medicine
2)Department of Neurology, Tohoku University Graduate School of Medicine
3)Department of Neurology, National Hospital Organization Miyagi Hospital
4)Department of Neurology, National Hospital Organization Yonezawa Hospital
5)Department of Neurology, Shonan Keiiku Hospital

We report an 18 year-old-male, who had been aware of decreased visual acuity for 6 months, newly presented with paresis and sensory disturbance in his right leg. On admission, his critical flicker frequency was reduced bilaterally, and his spinal cord MRI revealed T2-hyperintense lesions in cervical and thoracic cord with occasional contrast enhancements, but none of them were longitudinally extensive. There was no evidence of T2-hyperintense in his brain MRI. Anti-aquapolin-4 (AQP4) antibody was negative but the patient was positive for oligoclonal bands in his cerebrospinal fluid. The patient was tentatively diagnosed as opticospinal multiple sclerosis (OSMS). However, he later tuned out to be positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibody. The 2017 revised McDonald criteria don't take anti-MOG antibody into account in detail as to how clinicians should deal with patients fulfilling the MS criteria when they were also positive for anti-MOG antibody, because of its difficult problem of independence. So, we need to accumulate knowledge about these cases.
Full Text of this Article in Japanese PDF (1632K)

(CLINICA NEUROL, 58: 737|744, 2018)
key words: multiple sclerosis (MS), opticospinal multiple sclerosis (OSMS), neuromyelitis optica Spectrum Disorder (NMOSD), anti-myelin oligodendrocyte glycoprotein (MOG) antibody, MOG antibody-related disease

(Received: 13-May-18)